Post by Grafa United States

Elevance Health has reported another solid quarter, with Q2 2026 operating revenue of $49.8 billion and stronger-than-expected earnings supporting a higher full-year outlook. 🩺 Operating revenue rose 0.8% year-on-year, while diluted EPS came in at $6.71 and adjusted diluted EPS reached $7.45, helped by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit. The company lifted its full-year 2026 diluted EPS guidance to at least $20.10 and raised its adjusted diluted EPS target to at least $27, signaling confidence in its earnings trajectory. Management also increased its operating cash flow forecast to at least $6 billion, saying it is accelerating targeted investment into Carelon’s integrated healthcare solutions to deepen the link between health benefits and care delivery. Read the full story on Grafa – link in the comments.🔗 #ElevanceHealth #Healthcare #ManagedCare #Earnings #USMarkets #Grafa